MedTech Dive August 19, 2024
Using sound waves to break down tumor tissue can offer patients with liver cancer an alternative to surgery, radiation and chemotherapy.
Dive Brief:
- Histosonics, whose technology targets liver tumors with ultrasound pulses delivered from outside the body, has raised $102 million in new funding to support further development and commercial growth of the platform.
- The company’s histotripsy system, which gained de novo authorization in October from the Food and Drug Administration, employs sound waves to break down and destroy tumor tissue, offering a noninvasive alternative to cancer treatments such as surgery, radiation and chemotherapy, which can have severe side effects.
- The Series D financing will be used to advance work on the Edison histotripsy platform and support commercial growth...
Today's Sponsors
Today's Sponsor